A Study of AZD0486 Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
Status:
RECRUITING
Trial end date:
2031-11-26
Target enrollment:
Participant gender:
Summary
This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the AZD0486 plus rituximab combination compared to Investigator's choice of 3 standard immunochemotherapy regimen, conducted in participants with untreated FL.